Down-regulation of immune checkpoints by doxorubicin and carboplatin-containing neoadjuvant regimens in a murine breast cancer model.

Although doxorubicin showed a trend to decline the level of expression of CTLA-4 in 4T1 tumor tissue, no statistically significant alterations were evident among groups ( Figure 4 C ).

also in 53,322 other papers